Shuttle Pharmaceuticals ...
(SHPH)
undefined
undefined%
At close: undefined
0.68
0.35%
After-hours Dec 13, 2024, 06:21 PM EST
Company Description
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy.
Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers.
The company was founded in 2012 and is based in Rockville, Maryland.
Shuttle Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Aug 31, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Anatoly Dritschilo M.D. |
Contact Details
Address: One Research Court Rockville, Maryland United States | |
| Website | https://www.shuttlepharma.com |
Stock Details
| Ticker Symbol | SHPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001757499 |
| CUSIP Number | 825693203 |
| ISIN Number | US8256932034 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anatoly Dritschilo M.D. | Co-Founder, Chief Executive Officer & Chairman of the Board |
| Peter Dale Dritschilo M.B.A., M.D. | President & Chief Operating Officer |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder & Director |
| Dr. Mira Jung Ph.D. | Co-Founder & Chief Scientific Officer for Biology |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer & Chief Medical Officer |
| Gene Jung Esq. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 01, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 424B4 | Filing |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 8-K | Current Report |
| Oct 25, 2024 | D | Filing |